Functional Medicine · Hormonal Health

The Journal

by Dr. Natasha Ryan, ND

Hormone Therapy · FDA

Hormone Therapy and Breast Cancer Risk: What the FDA's Boxed Warning Change Means for You

4 min read

For more than 20 years, every box of estrogen for menopause carried the FDA's most serious warning: a black box citing breast cancer, heart disease, stroke, and dementia. That has changed. Here's what the FDA did, what it means, and what it doesn't mean.

What the FDA changed

On November 10, 2025, the FDA and the Department of Health and Human Services announced they would remove most of the boxed warning from menopausal hormone therapy. The decision followed a review of the research, an expert panel in July 2025, and a public comment period.

The language about cardiovascular disease, breast cancer, and probable dementia is being removed from the boxed warning. On February 12, 2026, the FDA approved the first updated labels for six products, covering combined estrogen-progestogen therapy, estrogen-alone therapy, progestogen used alongside estrogen, and vaginal estrogen. On October 30, 2026, three more products, all estrogen patches, received updated labels. Twenty-nine companies have submitted label changes so far.

The new labeling also recommends that systemic hormone therapy be started within 10 years of menopause onset or before age 60.

What did not change

  • The endometrial cancer warning stays on systemic estrogen-alone products. If you have a uterus, estrogen needs to be paired with a progestogen to protect the uterine lining.
  • The risks are still in the label. They moved out of the box and into the detailed prescribing information, where they can be discussed in context.
  • Hormone therapy is still not for everyone. A history of breast cancer, blood clots, stroke, liver disease, or unexplained vaginal bleeding still needs careful, individual evaluation.

Where the original warning came from

The boxed warning was added in 2003 after the Women's Health Initiative (WHI), a large trial that tested one specific combination: oral conjugated equine estrogens plus medroxyprogesterone acetate, a synthetic progestin. The average participant was in her 60s, often more than a decade past menopause.

The combined-therapy arm showed a small increase in breast cancer diagnoses. But the estrogen-alone arm, in women who'd had a hysterectomy, showed fewer breast cancer cases than placebo. Over the following two decades, researchers argued that the results had been applied too broadly to younger women and to different formulations. A 2026 review in Obstetrics & Gynecology described the warning as based on secondary outcomes and incompletely collected data.

So does hormone therapy cause breast cancer?

The honest answer is that it depends on the type, the dose, the progestogen used, how long you take it, and your personal risk.

  • Estrogen alone, in women without a uterus, has not shown increased breast cancer risk in the WHI.
  • Combined estrogen plus a synthetic progestin showed a small increase in the WHI.
  • Your own factors matter more than averages: family history, breast density, alcohol use, weight, and genetics.

Not everyone agrees with the FDA's decision

Many menopause specialists welcomed the change. Others, including Public Citizen's Health Research Group, criticized it for relying on an ad hoc expert panel and a literature review rather than new safety data or a formal advisory committee. The U.S. Preventive Services Task Force continues to recommend against hormone therapy for preventing chronic disease in postmenopausal women. Treating symptoms is a different question from prevention.

What this means for you

  1. Hormone therapy is back on the table for many women who were previously told it was too dangerous, especially those under 60 or within 10 years of menopause.
  2. The decision should be individual. Your symptoms, history, and goals matter more than a label.
  3. Formulation matters. Transdermal estradiol and micronized progesterone differ from the pills studied in the WHI. Ask what's being recommended and why.
  4. Timing matters. Starting closer to menopause appears to carry a better balance of benefits and risks.
  5. Keep up with screening. Mammograms and breast awareness remain important whether or not you use hormones.

If symptoms like brain fog in perimenopause, perimenopause rage and irritability, or loss of motivation in perimenopause are affecting your life, it's worth revisiting the conversation about hormone therapy with a clinician who knows the current evidence.

For more on how I work with women through this transition, see The Menopause Edge™.

Frequently Asked Questions

Did the FDA remove the black box warning on HRT?

Mostly. In November 2025 the FDA began removing cardiovascular disease, breast cancer, and probable dementia language from the boxed warning on menopausal hormone therapy. Updated labels were approved for six products in February 2026 and three more in October 2026. The endometrial cancer warning remains on systemic estrogen-alone products.

Does hormone therapy cause breast cancer?

It depends on the type. In the Women's Health Initiative, estrogen alone did not increase breast cancer, while estrogen combined with a synthetic progestin showed a small increase. Personal risk factors matter.

Is hormone therapy safe now?

For many healthy women under 60 or within 10 years of menopause, current evidence suggests benefits outweigh risks for symptom relief. It still isn't right for everyone, and the decision should be made with a clinician.

Why was the warning added in the first place?

It followed the 2002 Women's Health Initiative trial, which studied oral conjugated estrogens plus medroxyprogesterone acetate in women whose average age was in their 60s.

References

  1. U.S. Food and Drug Administration. HHS advances women's health, removes misleading FDA warnings on hormone replacement therapy. November 10, 2025. View source
  2. U.S. Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. February 12, 2026. View source
  3. FDA removes boxed warnings from 3 more menopausal hormone therapy products. Contemporary OB/GYN. October 30, 2026. View source
  4. Makary MA, Nguyen CP, Høeg TB, Tidmarsh GF. Updated labeling for menopausal hormone therapy. JAMA. 2026;335(2):117-118. View source
  5. Elimination of the black box warning on menopausal hormone therapy. Obstet Gynecol. 2026;147(5):642-646. View source
  6. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. View source
  7. Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long-term follow-up of the Women's Health Initiative randomized clinical trials. JAMA. 2020;324(4):369-380. View source
  8. Zeldes N, Steinbrook R. Outrage of the month: labeling changes to menopausal hormone therapy products. Public Citizen Health Letter, March 2026. View source